Investment Analysts’ Weekly Ratings Updates for Iovance Biotherapeutics (IOVA)

Several brokerages have updated their recommendations and price targets on shares of Iovance Biotherapeutics (NASDAQ: IOVA) in the last few weeks:

• 10/8/2026 – Iovance Biotherapeutics had its price target raised by Robert W. Baird from $6.00 to $11.00. They now have a “neutral” rating on the stock.
• 9/30/2026 – Iovance Biotherapeutics had its price target raised by Wells Fargo & Company from $14.00 to $18.00. They now have an “overweight” rating on the stock.
• 9/29/2026 – Iovance Biotherapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/29/2026 – Iovance Biotherapeutics had its price target raised by HC Wainwright from $9.00 to $20.00. They now have a “buy” rating on the stock.
• 9/24/2026 – Iovance Biotherapeutics is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $15.00 price target on the stock.
• 9/24/2026 – Iovance Biotherapeutics is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $15.00 price target on the stock.
• 9/17/2026 – Iovance Biotherapeutics had its price target raised by Barclays PLC from $13.00 to $15.00. They now have an “overweight” rating on the stock.
• 8/24/2026 – Iovance Biotherapeutics had its price target raised by TD Cowen from $7.00 to $10.00. They now have a “buy” rating on the stock.
• 8/20/2026 – Iovance Biotherapeutics had its price target raised by UBS Group AG from $4.00 to $7.00. They now have a “neutral” rating on the stock.
• 8/18/2026 – Iovance Biotherapeutics had its price target raised by Mizuho from $10.00 to $11.00. They now have an “outperform” rating on the stock.

Iovance Biotherapeutics, Inc is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. The company’s platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded in a manufacturing facility and reinfused to help the immune system recognize and attack cancer cells.

Iovance’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment with a PD-1-blocking antibody and, when applicable, a BRAF-targeted therapy.